Navigation Links
Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
Date:4/11/2012

WICHITA, Kan., April 11, 2012 /PRNewswire-USNewswire/ -- Riordan Clinic scientists Dr. Nina Mikirova, Dr. Joseph Casciari, and Dr. Ronald Hunninghake have patented a new technology that may help doctors determine the severity of fatigue in their patients.  The research, recently published in the January/February issue of the journal, Alternative Therapies, is entitled "The Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome by Serum Fluorescence Emission." 

Chronic fatigue syndrome (CFS) is characterized by long-lasting disabling fatigue. It includes non-specific symptoms such as weakness, malaise, subjective fever, sore throat, lymph node pain, and decreased memory. There are no conclusive diagnostic tests for CFS.  Since the underlying mechanism for CFS is not known, finding reliable biomarkers for diagnosing are important. 

The purpose of this study was to examine the use of serum nicotinamide adenine dinucleotide (NAD(P)H) levels as a metabolic marker of fatigue state and alterations in metabolism and homeostasis in CFS patients. 

The Riordan Clinic scientists have developed a method of determining NAD(P)H levels based on fluorescence emission of serum at 450 nm. Serum NAD(P)H concentrations were  compared for subjects with CFS and healthy controls.  NAD(P)H concentrations in the serum of CFS subjects averaged 8.0 +/- 1.4 (SD) uM while those in healthy controls averaged 10.8 +/- 0.8 (SD) uM, a statistically significant difference (p < 0.001). 

The sensitivity (detection of positives) and specificity (non-detection of negatives) of the test in matching CFS patients to control subjects at NAD(P)H cut-off of 9.5 uM were 0.73 and 0.98.   

The researchers also compared NAD(P)H concentrations to other endocrine and metabolic parameters. A factor
'/>"/>

SOURCE Riordan Clinic
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The ABC Clinical Guide to Herbs Now Available Online
2. First targeted and programmable nanomedicine to show clinical antitumor effects published
3. inVentiv Health Completes Acquisition of Kforce Clinical Research
4. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
5. New imaging technique moves from lab to clinic
6. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
7. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
8. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
9. Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference
10. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
11. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimestaâ„¢ for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... 28 To date, 60 specialty & fine,chemical ... are scheduled,to exhibit at the Pharma ChemOutsourcing Conference ... The conference and exhibition has already attracted more ... supplier community is attracted to,the high-quality show that ...
... Stem Cell,Holding, Inc. (OTC: NHGI - News) today announced ... Proteonomix, Inc. The change will also entail a change,in ... new name reflects the fact,that we are emerging out ... of our technologies. These technologies,relate in great part to ...
... Internationally Recognized Oncologists Will Offer Strategic Guidance on ... Picoplatin Clinical Development -, ... (Nasdaq: PARD ), a biopharmaceutical company focused,on oncology, today ... Board to help guide the Company,s expanding clinical,development strategy for ...
Cached Biology Technology:60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 3Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board 2Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board 3Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board 4Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board 5Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board 6
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Ind. - Purdue University scientists have improved a strain ... plant material by fermenting all five types of the ... agricultural and biological engineering; Miroslav Sedlak, a research assistant ... a research professor of chemical engineering, used genes from ...
... evolutionary systematists often use molecular methods, such like ... subspecies. These molecular methods are a flashy symbol ... draw interest of public and by laboratory scientists ... current research indicates that the picture painted by ...
... is very important in protecting against cancer given that ... is closely linked to the proliferation of tumour cells. ... by an international research team, the study served to ... it also becomes activated during the formation process of ...
Cached Biology News:New yeast can ferment more sugar, make more cellulosic ethan 2Molecular methods are not sufficient in systematics and evolution 2Molecular methods are not sufficient in systematics and evolution 3New function discovered in cancer prevention protein 2
... of Total Canine Endostatin. Canine ... Science products include a line of ... and reagents used for multiple research ... kits are ultra-sensitive, quick and dependable ...
... is a very sensitive immunohistochemical tool for ... both anti-von Willebrand Factor and anti-CD31 primary ... of species. This AP kit provides a ... frozen and paraffin-embedded sections in human (both ...
... Eagle's medium have been developed ... most widely used modification is ... a modification of Minimum Essential ... a higher concentration of vitamins ...
... OligoMix or individual RNA sequences from high throughput ... small RNAs from LC Sciences. These products provide ... millions) of DESIGNED sequences delivered in a microtube ... containing a single verified RNA sequence. This is ...
Biology Products: